Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel monotherapy in major depressive disorder
2018-000063-88Phase 3Terminated
- Sponsor
- Allergan
- Start
- Nov 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Rapastinel, Placebo and Vortioxetine (3 arms). Primary endpoint: Change from baseline in Montgomery-Asberg Depression Rating Scale total score at end of treatment. Started Nov 2018; status: terminated.
02
Drugs
rapastinelvortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-000063-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000063-88.